This company has shut down. Codiak Biosciences is no longer operating — its last tracked round was a Post-IPO Equity in 2022.
Explore the Startup GraveyardCodiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Codiak Biosciences has raised $20.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2022.
Codiak Biosciences's investors include ARCH Venture Partners, Fidelity, Flagship Pioneering, EcoR1 Capital, Alexandria Venture Investments.
Codiak Biosciences is headquartered in San Francisco, United States.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Codiak Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Codiak Biosciences — Funding & Investors." VCBacked, September 12, 2022, https://www.vcbacked.co/company/codiak-biosciences. Accessed July 20, 2026.
VCBacked. (2022). Codiak Biosciences — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/codiak-biosciences
{{cite web |title=Codiak Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/codiak-biosciences |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated